These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9076875)

  • 1. Exaggerated neurological side-effects of oral and intravesical oxybutynin in a patient with multiple sclerosis.
    Vaidyanathan S; Krishnan KR; Soni BM; Fraser MH
    Spinal Cord; 1997 Mar; 35(3):190-1. PubMed ID: 9076875
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
    Von Zweigbergk M; Nordin B; Jonsson S
    Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
    [No Abstract]   [Full Text] [Related]  

  • 3. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.
    Ferrara P; D'Aleo CM; Tarquini E; Salvatore S; Salvaggio E
    BJU Int; 2001 May; 87(7):674-8. PubMed ID: 11350411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism.
    Buyse G; Waldeck K; Verpoorten C; Björk H; Casaer P; Andersson KE
    J Urol; 1998 Sep; 160(3 Pt 1):892-6. PubMed ID: 9720583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
    Palmer LS; Zebold K; Firlit CF; Kaplan WE
    J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal oxybutynin (oxytrol) for urinary incontinence.
    Dull P
    Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in anticholinergic therapy delivery systems.
    Davila GW
    Geriatrics; 2002 May; 57 Suppl 1():29-34. PubMed ID: 12040601
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects.
    Bemelmans BL; Kiemeney LA; Debruyne FM
    Eur Urol; 2000 Jun; 37(6):709-13. PubMed ID: 10828672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
    Di Stasi SM; Giannantoni A; Vespasiani G; Navarra P; Capelli G; Massoud R; Stephen RL
    J Urol; 2001 Feb; 165(2):491-8. PubMed ID: 11176403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cutaneous administration rather than swallowing].
    Schubert-Zsilavecz M
    Krankenpfl J; 2005; 43(7-10):186. PubMed ID: 16515258
    [No Abstract]   [Full Text] [Related]  

  • 13. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin.
    Birns J; Lukkari E; Malone-Lee JG
    BJU Int; 2000 May; 85(7):793-8. PubMed ID: 10792154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical oxybutynin: practicalities of clinical use.
    Guerrero K; Emery S; Owen L; Rowlands M
    J Obstet Gynaecol; 2006 Feb; 26(2):141-3. PubMed ID: 16483973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction.
    Buyse G; Verpoorten C; Vereecken R; Casaer P
    J Urol; 1998 Sep; 160(3 Pt 2):1084-7; discussion 1092. PubMed ID: 9719281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children.
    Amark P; Bussman G; Eksborg S
    Eur Urol; 1998 Aug; 34(2):148-53. PubMed ID: 9693251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical therapy for the treatment of neurogenic bladder in children.
    Holland AJ; King PA; Chauvel PJ; O'Neill MK; McKnight DL; Barker AP
    Aust N Z J Surg; 1997 Oct; 67(10):731-3. PubMed ID: 9322726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute-angle closure glaucoma as a side-effect of oxybutynin.
    Sung VC; Corridan PG
    Br J Urol; 1998 Apr; 81(4):634-5. PubMed ID: 9598644
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
    Lose G; Nørgaard JP
    BJU Int; 2001 Jun; 87(9):767-73. PubMed ID: 11412211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.